Abstract
The natural history of Crohn's disease is characterized by recurrent exacerbations. A small, but significant, number of pediatric patients with Crohn's disease are resistant to standard medical therapies. The goal of therapy in pediatric patients is not only to achieve and maintain clinical remission, but also to promote growth, development and improve quality of life. All of this needs to be achieved within a relatively short window of opportunity, before growth and development deficiencies become permanent. The standard therapy for pediatric patients with Crohn's disease consists of 5-aminosalicylic-acid compounds, antibiotics and enteral nutrition. Enteral nutrition has an excellent adverse-effect profile and, in addition to its therapeutic effect, positively impacts growth and nutritional status. Immunomodulating medications, such as azathioprine, 6-mercaptopurine and methotrexate, are frequently used to maintain remission, and to treat corticosteroid-dependent and perianal disease. Recently, biologic treatment with the anti-tumor-necrosis-factor-α antibody infliximab has dramatically changed the therapeutic approach. The long-term safety of this therapy still needs to be established. Limited data are available on other biologic therapies, which, at this point in time, are considered experimental and are only available through clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jenkins HR (2001) Inflammatory bowel disease. Arch Dis Child 85: 435–437
Kugathasan S et al. (2003) Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143: 525–531
Mamula P et al. (2003) Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 32: 967–995
Barton JR and Ferguson A (1990) Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med 75: 423–439
Mamula P et al. (2002) Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 97: 2005–2010
Markowitz J et al. (2002) Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990–2000. Am J Gastroenterol 97: 928–932
Barabino A et al. (2002) Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 16: 1125–1130
Seidman E et al. (1991) Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 12: 424–438
Kanof M et al. (1988) Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 95: 1523–1527
Hyams JS et al. (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12: 439–447
Stephens M et al. (2001) Growth failure in the child with inflammatory bowel disease. Semin Gastrointest Dis 12: 253–262
Sentongo T et al. (2000) Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 31: 33–40
Henker J (1996) Therapy with recombinant growth hormone in children with Crohn disease and growth failure. Eur J Pediatr 155: 1066–1067
Calenda KA et al. (2005) Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 11: 435–441
Borrelli O et al. (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 36: 342–347
Brain CE and Savage MO (1994) Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 8: 83–100
Baldassano R et al. (2002) Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 34: 245–248
Semeao E et al. (1997) Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 112: 1710–1713
Semeao EJ et al. (1999) Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr 135: 593–600
Walker-Smith JA (1996) Management of growth failure in Crohn's disease. Arch Dis Child 75: 351–354
Faubion WA Jr et al. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255–260
Escher JC (2004) Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 16: 47–54
Schoon EJ et al. (2005) Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 3: 113–121
Cino M and Greenberg GR (2002) Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 97: 915–921
Kundhal P et al. (2001) Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 33: 75–80
Griffiths A et al. (1995) Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108: 1056–1067
Heuschkel RB et al. (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 31: 8–15
Ludvigsson JF et al. (2004) Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr 93: 327–335
Pearson DC et al. (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132–142
Markowitz J et al. (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119: 895–902
Jacobstein DA et al. (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442–446
Kirschner B (1998) Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115: 813–821
Dubinsky MC et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705–713
Regueiro M and Mardini H (2002) Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 35: 240–244
Wright S et al. (2004) Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53: 1123–1128
Fraser AG (2003) Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 15: 225–231
Feagan BG et al. (1995) Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332: 292–297
Mack DR et al. (1998) Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 132: 830–835
Rosh JR et al. (2003) Efficacy of methotrexate as a maintenance agent in pediatric Crohn's disease [abstract]. J Pediatr Gastroenterol Nutr 37: A392
Stephens MC et al. (2005) The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 40: 445–449
Kurnik D et al. (2003) Bioavailability of oral versus subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 18: 57–63
Mahdi G et al. (1996) Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol 91: 1355–1359
Ramakrishna J et al. (1996) Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 22: 296–302
Nahar IK et al. (2003) Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 37: 1256–1265
Lamireau T et al. (2004) Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 10: 745–750
Baldassano R et al. (2003) Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 98: 833–838
de Ridder L et al. (2004) Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 39: 46–52
Escher JC et al. (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9: 34–58
Kooros K and Katz AJ (2004) Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis 10: 417–420
Cezard JP et al. (2003) A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 36: 632–636
Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549
Miele E et al. (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502–508
Kugathasan S et al. (2000) Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 95: 3189–3194
Lionetti P et al. (2003) Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 18: 425–431
Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876–885
Wolfe F and Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740–1751
Schaible TF (2000) Long term safety of infliximab. Can J Gastroenterol 14 (Suppl C): 29C–32C
Colombel JF et al. (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19–31
Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345: 1098–1104
Lee JH et al. (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 46: 2565–2570
Slifman NR et al. (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum 48: 319–324
Cohen RD et al. (2000) Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95: 3469–3477
Crandall WV and Mackner LM (2003) Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17: 75–84
Jacobstein DA et al. (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442–446
Kugathasan S et al. (2002) Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97: 1408–1414
Miele E et al. (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502–508
Stephens M et al. (2003) Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 98: 104–111
Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485–1493
Mamula P et al. (2004) CDP571, a humanized anti-tumor necrosis factor-α monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 10: 723–730
Mian S and Baron H (2005) Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 41: 357–359
Papadakis KA et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75–79
Hyams J et al. (2004) A phase II, multicenter, open-label study of the safety, tolerability, and effectiveness of natalizumab in adolescents with moderately to severely active Crohn's disease. J Pediatr Gastroenterol Nutr 39 (Suppl 1): S49
Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368
Oyama Y et al. (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128: 552–563
Korzenik JR et al. (2005) Sargramostim for active Crohn's disease. N Engl J Med 352: 2193–2201
Sentongo TA et al. (2000) Growth after intestinal resection for Crohn's disease in children, adolescents, and young adults. Inflamm Bowel Dis 6: 265–269
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Homan, M., Baldassano, R. & Mamula, P. Managing complicated Crohn's disease in children and adolescents. Nat Rev Gastroenterol Hepatol 2, 572–579 (2005). https://doi.org/10.1038/ncpgasthep0338
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0338
This article is cited by
-
Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon
Supportive Care in Cancer (2016)
-
Elemental diet moderates 5-fluorouracil-induced gastrointestinal mucositis through mucus barrier alteration
Cancer Chemotherapy and Pharmacology (2015)
-
GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis
Inflammation Research (2011)